Cash & Equivalents
Alnylam Pharmaceuticals Cash & Equivalents increased by 3.2% to $1.71B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 67.5%, from $1.02B to $1.71B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 27.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $748.07M | $1.10B | $822.15M | $536.26M | $577.74M | $1.08B | $868.56M | $674.41M | $659.98M | $1.04B | $814.88M | $684.72M | $971.19M | $1.10B | $968.65M | $1.02B | $1.12B | $1.49B | $1.66B | $1.71B |
| QoQ Change | — | +46.6% | -25.0% | -34.8% | +7.7% | +86.1% | -19.2% | -22.4% | -2.1% | +56.9% | -21.3% | -16.0% | +41.8% | +13.5% | -12.1% | +5.5% | +9.2% | +33.8% | +11.1% | +3.2% |
| YoY Change | — | — | — | — | -22.8% | -1.9% | +5.6% | +25.8% | +14.2% | -3.7% | -6.2% | +1.5% | +47.2% | +6.5% | +18.9% | +49.3% | +14.9% | +35.4% | +71.2% | +67.5% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's cash & equivalents?
- Alnylam Pharmaceuticals (ALNY) reported cash & equivalents of $1.71B in Q1 2026.
- How has Alnylam Pharmaceuticals's cash & equivalents changed year-over-year?
- Alnylam Pharmaceuticals's cash & equivalents increased by 67.5% year-over-year, from $1.02B to $1.71B.
- What is the long-term trend for Alnylam Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's cash & equivalents has grown at a 27.2% compound annual growth rate (CAGR), from $499.05M to $1.66B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.